Premium
Convalescent plasma for pediatric patients with SARS‐CoV‐2‐associated acute respiratory distress syndrome
Author(s) -
Diorio Caroline,
Anderson Elizabeth M.,
McNerney Kevin O.,
Goodwin Eileen C.,
Chase Julie C.,
Bolton Marcus J.,
Arevalo Claudia P.,
Weirick Madison E.,
Gouma Sigrid,
Vella Laura A.,
Henrickson Sarah E.,
Chiotos Kathleen,
Fitzgerald Julie C.,
Kilbaugh Todd J.,
John Audrey R. Odom,
Blatz Allison M.,
Lambert Michele P.,
Sullivan Kathleen E.,
Tartaglione Margaret R.,
Zambrano Danielle,
Martin Meghan,
Lee Jessica H.,
Young Pampee,
Friedman David,
SesokPizzini Deborah A.,
Hensley Scott E.,
Behrens Edward M.,
Bassiri Hamid,
Teachey David T.
Publication year - 2020
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.28693
Subject(s) - medicine , covid-19 , antibody , acute respiratory distress , respiratory distress , respiratory system , randomized controlled trial , convalescent plasma , clinical trial , coronavirus , intensive care medicine , disease , immunology , anesthesia , lung , infectious disease (medical specialty)
There are no proven safe and effective therapies for children who develop life‐threatening complications of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). Convalescent plasma (CP) has demonstrated potential benefit in adults with SARS‐CoV‐2, but has theoretical risks.We present the first report of CP in children with life‐threatening coronavirus disease 2019 (COVID‐19), providing data on four pediatric patients with acute respiratory distress syndrome. We measured donor antibody levels and recipient antibody response prior to and following CP infusion. Infusion of CP was not associated with antibody‐dependent enhancement (ADE) and did not suppress endogenous antibody response. We found CP was safe and possibly efficacious. Randomized pediatric trials are needed.